On June 20, the highly anticipated U.S. magazine Pharm Exec released its "2025 Top 50 Global Pharma Companies" list, with Sino Biopharm (1177.HK) making the list for the seventh consecutive year. This year, a total of 6 Chinese companies were listed. Sino Biopharm ranked 39th globally and 2nd domestically. Against a background of increasing industry disruption, restructuring, and transformation, Sino Biopharm is focusing on its core areas of strength and continuously enhancing its innovation capabilities. Driven by the rising proportion of revenue from innovative drugs and the outstanding performance of its innovation pipeline on the international stage, the company is accelerating its transformation into an innovative pharmaceutical enterprise with global competitiveness.

This year marks the 25th time Pharm Exec magazine has released its "Top 50 Global Pharma Companies" list, which ranks the world's top 50 pharmaceutical companies based on their global sales performance of prescription drugs. As a bellwether for the global pharmaceutical industry, this year's list reflects two core trends: traditional giants are consolidating their advantages through pipeline iteration, while emerging challengers are driving disruptive innovation in the industry with technology.

The Rise of Chinese Pharmaceutical Companies: A Leap from Quantity to Quality

From the perspective of Chinese pharmaceutical companies, this year saw the highest number of listed companies, with a total of 6 making the list. This demonstrates that Chinese pharmaceutical companies are transitioning from "followers" to participants in global competition, achieving a leap from quantity to quality.

Sino Biopharm has prominent advantages in core areas such as oncology and liver disease. Anlotinib Hydrochloride Capsules (Fukewei^®) and Magnesium Isoglycyrrhizinate Injection (Tianqing Ganmei^®) are the company's top two products by prescription drug sales revenue, respectively. At the recently concluded 2025 Annual Meeting of American Society of Clinical Oncology (ASCO), Anlotinib demonstrated strong development potential, with 9 studies selected for oral presentations, the most for any domestically developed innovative drug. The "Defu Combination (Benmelstobart combined with Anlotinib)" defeated Keytruda and Toripalimab combined with chemotherapy in two separate head-to-head pivotal Phase III clinical trials.

Information released by Pharm Exec shows that the total volume of pipeline assets in the oncology field is on a yearly upward trend, reaching 39% in 2024. Focusing on the oncology track, Sino Biopharm has reported positive clinical data for several products under development, including the HER2 bispecific Antibody-Drug Conjugate (ADC) (TQB2102), CCR8 monoclonal antibody (LM108), and PD-1/TGF-β bispecific antibody (TQB2868). Other investigational products, such as the EGFR/c-Met bispecific ADC (TQB6411) and the innovative PROTAC drug (TQB3019), have also recently received their first clinical trial approvals, demonstrating the company's comprehensive innovation capabilities across multiple neoplasm types.

Sino Biopharm: A Paradigm for the Transformation of an Innovative Pharmaceutical Company

As a paradigm for the transformation of Chinese innovative pharmaceutical companies, Sino Biopharm is consolidating its competitive advantages through strategies of comprehensive innovation, internationalization, and digitalization. Focusing on a development strategy of comprehensive innovation, the company achieved double-digit growth in both revenue and net profit in 2024, with revenue from innovative products surpassing the RMB 12 billion mark for the first time. As one of China's largest prescription drug companies, the company plans to launch approximately 5 innovative drugs annually over the next three years. The clear goal is for the revenue share of innovative drugs to exceed 50% by 2025 and further increase to 60% by 2027, by which time the number of the company's innovative products will exceed 30.

Since the beginning of this year, out-licensing has become one of the company's core strategic goals. The company expects an out-licensing deal to be finalized soon, aiming to significantly expand its international business footprint and open up a second growth curve for its performance.

Facing the "AI + Pharma" industrial revolution, Sino Biopharm has taken the lead in completing its digital layout. In recent years, the company has established external collaborations with numerous AI technology companies such as Huawei and Alibaba. Internally, it is also continuously exploring deeper applications across the entire business chain, including AI-assisted drug screening, development of R&D intelligent agents, clinical trial research, smart manufacturing, and corporate management.

In 2025, the global pharmaceutical industry is at a critical intersection of "structural reshaping + technological innovation". Global competition centered on keywords such as "biosimilars" and "AI-driven R&D" will intensify. Sino Biopharm will continue to promote the transformation of innovative achievements, accelerate its strategic pace of comprehensive innovation, internationalization, and digitalization, and is committed to bringing more and better treatment options to patients worldwide.

Declaration:

1. This press release is intended to facilitate the communication and exchange of medical information and is for reference by healthcare professionals only. It is not for advertising purposes.

2. The company does not recommend any drugs and/or indications.

3. The information contained in this press release is for reference only and cannot replace professional medical guidance in any way, nor should it be considered as a diagnosis or treatment recommendation. If you wish to understand specific information about disease diagnosis and treatment, please follow the advice or guidance of a doctor or other healthcare professional.

Forward-Looking Statements:

This press release contains certain forward-looking statements, including statements regarding the clinical development plans, expectations of clinical benefits and advantages, commercialization outlook, the likelihood of clinical benefit for patients, and potential commercial opportunities for [Anlotinib Hydrochloride Capsules, Magnesium Isoglycyrrhizinate Injection, Benmelstobart Injection, TQB2102, LM108, TQB2868, TQB6411, TQB3019]. Words such as "expect", "believe", "continue", "may", "estimate", "hope", "intend", "plan", "potential", "predict", "project", "should", "will", "propose", and similar expressions are intended to identify forward-looking statements, but not all forward-looking statements contain these identifying words. These forward-looking statements are predictions or expectations made by the company based on currently available data and information, and actual results may differ materially from these forward-looking statements due to uncertainties or risks such as policy, R&D, market, and regulatory factors. Current or potential investors are advised to carefully consider the potential risks and should not place undue reliance on the forward-looking statements in this press release, which contain information only as of the date of this press release. Unless required by law, the company undertakes no obligation to update or revise any forward-looking statements in this press release as a result of new information, future events, or other circumstances.

Source: Official website of Pharm Exec